Health Care·Biotechnology·$20.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.39 | N/A | -8.33% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.39 | N/A | -8.33% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over recent performance and highlighted the need for strategic adjustments. They focused on long-term goals despite short-term setbacks.
Management acknowledged challenges in meeting earnings expectations.
They emphasized ongoing efforts to improve operational efficiency.
Future growth strategies were discussed, but specifics were limited.
This earnings report indicates that Moderna is facing challenges, particularly in profitability as reflected in the missed EPS. The lack of revenue figures and guidance leaves investors uncertain about the company's immediate future. The stock reaction was not specified, but the overall tone suggests caution moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MCCORMICK & CO INC Class N
Mar 24, 2009